CB-86 is a resorcinol-anandamide hybrid compound that acts as a partial agonist for the central cannabinoid (CB1 ) receptor and a neutral antagonist for the peripheral cannabinoid (CB2 ) receptor with Ki values of 5.6 and 7.9 nM, respectively. Its demonstrated potency is similar to that of WIN 55,212-2 (Ki= 21 and 2. nM for CB1 and CB2, respectively). CB-86 (1 mg/kg) exhibits antinociceptive effects in mice treated with formalin.
1. Brizzi, A., et al. 2009. J. Med. Chem. 52: 2506-2514. PMID: 19331413